Tailored radiation beams aim to boost liver cancer treatment
NCT ID NCT03896646
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests whether giving liver cancer patients a personalized dose of radiation (Yttrium-90) can improve tumor shrinkage compared to standard dosing. The study includes 42 adults with advanced liver cancer that cannot be removed by surgery. Researchers use special scans to tailor the radiation dose to each patient's tumor and liver function, aiming to maximize effectiveness while minimizing harm.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Yttrium-90 radioembolization with personalized dosimetry
- What this could lead to
- If successful, this could make radiation therapy more effective for liver cancer patients who cannot have surgery, potentially improving tumor shrinkage and survival.
- What could go wrong
- This is a small, early-phase trial with only 42 participants, so results may not apply to everyone. Personalized dosing may not improve outcomes and could still cause liver damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III HEPATOCELLULAR CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an IDO1 inhibitor boost immunotherapy against liver cancer?
- AI takes on liver cancer: could a computer help pick the right immunotherapy?
- Immunotherapy combo tested against untreatable liver cancer
- New drug zanzalintinib tested for advanced liver cancer
- Liver cancer drug combo shows promise in large trial
- New hope for liver cancer patients with cirrhosis? tiny trial tests drug duo